Can SARS-CoV-2 change individual radiation sensitivity of the patients recovered from COVID-19? (experimental and theoretical background).

Q3 Medicine

Experimental oncology Pub Date : 2021-09-01 DOI:10.32471/exp-oncology.2312-8852.vol-43-no-3.16554

V F Chekhun, E A Domina

{"title":"Can SARS-CoV-2 change individual radiation sensitivity of the patients recovered from COVID-19? (experimental and theoretical background).","authors":"V F Chekhun, E A Domina","doi":"10.32471/exp-oncology.2312-8852.vol-43-no-3.16554","DOIUrl":null,"url":null,"abstract":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Science of Ukraine has been studying the mechanisms and specificities of individual radiation sensitivity (IRS) formation in professionals who work in the field of ionizing radiation, cancer patients and representatives of other population groups. Our data based on the use of G2-test in in vitro irradiated blood lymphocytes in late G2-period of cell cycle indicated an increased carcinogenic risk in professionals with high IRS. We suggest that the COVID-19 pandemic could make significant adjustments in the formation of IRS in professionals who have survived the disease and continue to work with ionizing radiation (IR). Increased systemic inflammatory activity, which persists for a long time in COVID-19 patients, in combination with low-dose range irradiation (professionals who continue to work with IR) and with local irradiation in the high-dose range (radiation therapy for cancer patients) may affect IRS. Repeated determination of IRS in professionals who have had COVID-19 infection, using chromosomal G2-radiation sensitivity assay will answer the question: can SARS-CoV-2 coronavirus affect the IRS? The proposed hypothesis of the radiosensitivity evolution needs further experimental validation using a set of radiobiological indices to clarify the mechanism of IRS formation following COVID-19 infection. The detected changes (increase) of human IRS after COVID-19 must be taken into account for personalized planning of radiotherapy of COVID-19 cancer patients.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"43 3","pages":"277-280"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Science of Ukraine has been studying the mechanisms and specificities of individual radiation sensitivity (IRS) formation in professionals who work in the field of ionizing radiation, cancer patients and representatives of other population groups. Our data based on the use of G₂-test in in vitro irradiated blood lymphocytes in late G₂-period of cell cycle indicated an increased carcinogenic risk in professionals with high IRS. We suggest that the COVID-19 pandemic could make significant adjustments in the formation of IRS in professionals who have survived the disease and continue to work with ionizing radiation (IR). Increased systemic inflammatory activity, which persists for a long time in COVID-19 patients, in combination with low-dose range irradiation (professionals who continue to work with IR) and with local irradiation in the high-dose range (radiation therapy for cancer patients) may affect IRS. Repeated determination of IRS in professionals who have had COVID-19 infection, using chromosomal G₂-radiation sensitivity assay will answer the question: can SARS-CoV-2 coronavirus affect the IRS? The proposed hypothesis of the radiosensitivity evolution needs further experimental validation using a set of radiobiological indices to clarify the mechanism of IRS formation following COVID-19 infection. The detected changes (increase) of human IRS after COVID-19 must be taken into account for personalized planning of radiotherapy of COVID-19 cancer patients.

查看原文本刊更多论文

SARS-CoV-2是否会改变COVID-19康复患者的个体辐射敏感性?(实验和理论背景)。

乌克兰国家科学院R.E. Kavetsky实验病理学、肿瘤学和放射生物学研究所一直在研究电离辐射领域工作的专业人员、癌症患者和其他人群代表的个体辐射敏感性(IRS)形成的机制和特异性。我们的数据基于在细胞周期g2期后期体外辐照的血液淋巴细胞中使用的g2试验表明，高IRS的专业人员致癌风险增加。我们认为，COVID-19大流行可能会对那些幸存下来并继续从事电离辐射工作的专业人员的IRS形成产生重大调整。在COVID-19患者中持续很长时间的全身性炎症活动增加，与低剂量范围的照射(继续从事IR工作的专业人员)和高剂量范围的局部照射(癌症患者的放射治疗)相结合，可能会影响IRS。使用染色体g2辐射敏感性试验反复测定COVID-19感染的专业人员的IRS将回答以下问题:SARS-CoV-2冠状病毒会影响IRS吗?提出的辐射敏感性进化假说需要进一步的实验验证，使用一套放射生物学指标来阐明COVID-19感染后IRS形成的机制。COVID-19后检测到的人类IRS变化(增加)必须考虑到COVID-19癌症患者的个性化放疗计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.